Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Prediction, detection, and validation of isotope peaks in mass spectrometry data (Supplemental data for manuscript)

ABSTRACT: Mass spectrometry is a key analytical platform for metabolomics. The precise quantification and identification of small molecules is a prerequisite for elucidating the metabolism and the detection, validation, and evaluation of isotope clusters in LC-MS data is important for this task. Here, we present an approach for the improved detection of isotope clusters using chemical prior knowledge and the validation of detected isotope clusters depending on the substance mass using database statistics. We find remarkable improvements regarding the number of detected isotope clusters and are able to predict the correct molecular formula in the top three ranks in 92% of the cases. We make our methodology freely available as part of the Bioconductor packages xcms and CAMERA.

INSTRUMENT(S): micrOTOF-Q II ESI-Qq-TOF (Bruker)

SUBMITTER: Steffen Neumann

PROVIDER: MTBLS381 | MetaboLights | 2016-10-30

REPOSITORIES: MetaboLights

ACCESS DATA

Json Xml

Similar Datasets

Transcription profiling of expressed human chromosome 21 genes in transchromosomic mouse embryos carrying a freely segregating copy of Hsa21

Project description:Detection of expressed human chromosome 21 genes in transchromosomic mouse embryos carrying a freely segregating copy of Hsa21.

2005-11-19 | E-MEXP-409 | biostudies-arrayexpress

Validation data for Lawrence Livermore Microbial Detection Arrays

Project description:This SuperSeries is composed of the following subset Series: GSE24626: Validation data for Lawrence Livermore Microbial Detection Array version 2 GSE24699: Validation data for Lawrence Livermore Microbial Detection Array version 1 Refer to individual Series

2010-10-15 | E-GEOD-24700 | biostudies-arrayexpress

Comparison of proteomic sample preparation and data analysis methods by means of human follicular fluids

Project description:In-depth proteome exploration of complex body fluids is a challenging task that requires optimal sample preparation and analysis in order to reach novel and meaningful insights. Analysis of follicular fluids is similarly difficult as that of blood serum due to the ubiquitous presence of several highly abundant proteins and a wide range of protein concentrations. Therefore, the accessibility of this complex body fluid for liquid chromatography-tandem mass spectrometry (LC/MS/MS) analysis is a challenging opportunity to gain insights into the physiological status or to identify new diagnostic and prognostic markers for e.g. the treatment of infertility. We compared different sample preparation methods (FASP, eFASP and in-solution digestion) and three different data analysis software packages (Proteome Discoverer with SEQUEST and Mascot, Maxquant with Andromeda) in conjunction with semi- and full-tryptic databank search approaches in order to obtain a maximum coverage of the proteome.

2018-12-04 | PXD009061 | Pride

Validation data for Lawrence Livermore Microbial Detection Array version 2

Project description:Validation data for Lawrence Livermore Microbial Detection Array version 2

| PRJNA133581 | ENA

Validation data for Lawrence Livermore Microbial Detection Array version 1

Project description:Validation data for Lawrence Livermore Microbial Detection Array version 1

| PRJNA133637 | ENA

Development of an exosomal gene signature to detect residual disease in dogs with osteosarcoma using a novel xenograft platform and machine learning [mouse data]

Project description:We developed a method using canine osteosarcoma in mouse xenografts to distinguish tumor-derived from host-response exosomal mRNAs. The model allows for the identification of canine osteosarcoma-specific gene signatures by RNA sequencing and a species-differentiating bioinformatics pipeline. An osteosarcoma-associated signature consisting of five gene transcripts was validated in dogs with osteosarcoma. Serum/plasma exosomes were isolated from 53 dogs in distinct clinical groups (“healthy”, “osteosarcoma”, “other bone tumor”, or “non-neoplastic disease”). Pre-treatment samples from osteosarcoma cases were used as the training set and a validation set from post-treatment samples was used for testing, classifying as “osteosarcoma–detected” or “osteosarcoma–NOT detected”. Dogs in a validation set whose post-treatment samples were classified as “osteosarcoma–NOT detected” had longer remissions, up to 15 months after treatment. In conclusion, we identified a gene signature predictive of molecular remissions with potential applications in the early detection and minimal residual disease settings. These results provide proof-of-concept for our discovery platform and its utilization in future studies to inform cancer risk, diagnosis, prognosis, and therapeutic response.

2021-09-03 | GSE183190 | GEO

Development of an exosomal gene signature to detect residual disease in dogs with osteosarcoma using a novel xenograft platform and machine learning [canine data]

2021-09-03 | GSE183189 | GEO

Next Generation Sequencing of langerhans islets of miR-17-92/106b KO vs control

Project description:NGS was used in order to discover novel downstream targets of the miR-17-92/106b clusters.

2019-04-24 | GSE126516 | GEO

miRNA profiling data of mouse bone marrow samples four days post 5-FU treatment versus untreated controls

Project description:To identify miRNAs that regulate hematopoietic response after 5-FU-induced injury, we analyzed miRNA expression changes in bone marrow cells from mice with or without 5-FU treatment. Global miRNA expression profiling of the 5-FU and untreated cohorts showed that 92 miRNAs (among 168 that passed the detection threshold) were significantly upregulated or downregulated, with false discovery rates < 5%.

2012-09-24 | GSE39211 | GEO

SNP chip data of MCL

Project description:Mantle cell lymphoma (MCL) is a lymphoma characterized by aberrant activation of CCND1/cyclin D1 followed by sequential genetic abnormalities. Genomic abnormalities in MCL have been extensively examined by classical cytogenetics and microarray-based comparative genomic hybridization techniques, pointing out a number of alterations in genomic regions that correlate with the neoplastic phenotype and survival. Recently, single nucleotide polymorphism genomic microarrays (SNP-chip) have been developed and used for analysis of cancer genomics. This technique allows detection of genomic changes with higher resolution, including loss of heterozygosity without changes of gene dosage, so-called acquired uniparental disomy (aUPD). As a result of the analysis, known alterations were confirmed by SNP arrays, including deletion of INK4A/ARF, duplication/amplification of MYC, deletion of ATM, and deletion of TP53. We also identified a duplication/amplification that occurred at 13q involving oncogenic microRNA, miR17-92. We found other genomic abnormalities, including duplication/amplification of cyclin D1, del(1p), del(6q), dup(3q) and dup(18q). Our SNP-chip analysis detected these abnormalities at high resolution, allowing us to narrow the size of the commonly deleted regions, including 1p and 6q. Our SNP-chip analysis detected a number of aUPD sites, including whole chromosome 9 aUPD and 9p aUPD. We also found an MCL case with 19p, leading to homozygous deletion of TNFSF genes. keyword: SNP-chip; Kawmata_MCL

2009-11-13 | GSE18820 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data